Keywords: prosthodontics, randomized controlled clinical trial, single implant
Purpose: To determine the effect of 0.7- and 2.4-mm transmucosal abutment height titanium bases on the crestal bone stability and peri-implant soft tissue condition of bone-level implants with platform switching in patients with vertically thick soft tissues.
Materials and methods: Sixty bone-level platform-switched implants were placed in the molar and premolar regions of both arches in 60 patients. All epicrestally inserted nonsubmerged implants had a 4.1-mm diameter and, after osteointegration, were randomly allocated into two groups: (1) the short group, with a titanium base of 0.7-mm transmucosal abutment height, and (2) the high group with a 2.4-mm height. Monolithic zirconia restorations were fabricated for all implants. Parallel intraoral radiographs were obtained after the delivery of restorations (T1) and after 1 year (T2). Crestal bone levels and peri-implant soft tissue conditions were calculated for each implant. The significance level was set at α = .05.
Results: After 1 year, 55 patients were evaluated, with a mean bone loss of 0.6 ± 0.51 mm (median: 0.71, range: 0 to 2.09 mm) in the short group (23 patients) and 0.45 ± 0.59 mm (median: 0.65, range: 0 to 2.12 mm) in the high group (22 patients), showing no significant difference between groups (P = .168). A significant increase in marginal bone height was noted between the T1 and T2 time points in the short and high (P = .029 and .001, respectively) groups. The peri-implant soft tissue health parameters did not show statistically significant differences.
Conclusion: Crestal bone stability after 1 year of follow-up around epicrestally placed platform-switched implants is not influenced by transmucosal abutment height, if the vertical soft tissue thickness is ≥ 3 mm.